Susan A. McCloskey, MD
Postoperative radiation in breast cancer has become a personalized process, even enabling physicians to identify patients with ductal carcinoma in situ (DCIS) who have smaller incremental benefits and can potentially omit radiotherapy, says Susan A. McCloskey, MD.
on Breast Cancer, McCloskey, assistant professor of radiation oncology, University of California, Los Angeles (UCLA), Jonsson Comprehensive Cancer Center, discussed the use of postoperative radiation in patients with breast cancer.
OncLive: Please provide an overview of your presentation.
: Postoperative radiation is a large topic, and we use radiation in different clinical circumstances—be it after lumpectomy, mastectomy for DCIS, or for more locally advanced invasive disease. I wanted to cover a little bit about all of those clinical scenarios to inform the audience of situations in which radiation is appropriate to consider, when it may be appropriate to forego, and how we can tailor our radiation recommendations to the population at hand. I also spoke about some technological advances that make radiation a much better experience than it has historically been for women.
Can you elaborate on some of these data?
The thing that is striking to me is that there have been many recent advances, across the spectrum of clinical scenarios, in which we give radiation. Physicians have identified the subsets of women with early-stage disease with DCIS who have smaller incremental benefits and can potentially benefit from the omission of radiation therapy.
... to read the full story